| Name | Title | Contact Details |
|---|
ProPhase Labs (NASDAQ: PRPH) is a diversified medical science and technology company. The Company`s laboratory testing subsidiary, ProPhase Diagnostics, offers SARS-CoV-2 (COVID-19) and COVID-19 viral mutation PCR tests through both saliva and nasal swab methods at its CLIA certified laboratories. Critical to Covid testing, results are typically provided in under 24 hours. ProPhase Diagnostics also provides Respiratory Pathogen Panel (RPP) Molecular tests including Influenza A and B and others. ProPhase Labs researches, develops, manufactures, distributes, markets and sells OTC consumer healthcare products and dietary supplements, including dietary supplements under the TK Supplements® brand. The Company actively pursues strategic investments and acquisition opportunities for other companies, technologies and products.
Calm - Apple`s 2017 iPhone App of the Year! Our mission is to make the world happier and healthier through the superpower of Calm.
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.
Clearway Health partners with hospitals and health systems to build or strengthen their own specialty pharmacy program, improve access to care and provide personalized support to vulnerable patients, families, providers and care managers to eliminate b...
Medavie EMS is a health care delivery and management company based in Dartmouth, Nova Scotia, Canada. We have a team of management staff that specializes in the areas of project management, planning, education, human resources, communications finance, physical resources, process design, facilitation, reporting, and information technology. Currently, Medavie EMS is responsible to deliver EMS in Nova Scotia, New Brunswick, Prince Edward Island, the District Municipality of Muskoka in Ontario, the Municipality of Chatham-Kent in Ontario, Elgin County in Ontario, Saskatoon and surrounding areas in Saskatchewan, as well as, communities across eastern Alberta. Each of these systems is managed by subsidiary companies which have established contracts with governments (provincial and municipal) or health authorities. In addition, Medavie EMS operates a patient transfer service in Massachusetts headquartered in Boston. Combined these companies directly employ or manage a total staff of approximately 3800, 550 of whom are in the US.